Presented in part at the 33rd Annual Meeting of the Japanese Society for Apheresis held November 9–12, 2012 in Nagasaki, Japan.
Granulocyte and Monocyte Adsorption Apheresis for Refractory Skin Diseases due to Activated Neutrophils, Psoriasis, and Associated Arthropathy
Article first published online: 7 OCT 2013
© 2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis
Therapeutic Apheresis and Dialysis
Special Issue: Contributions from the 33rd Annual Meeting of the Japanese Society for Apheresis. Guest Editor: Hidenori Matsuo
Volume 17, Issue 5, pages 477–483, October 2013
How to Cite
Sakanoue, M., Takeda, K., Kawai, K. and Kanekura, T. (2013), Granulocyte and Monocyte Adsorption Apheresis for Refractory Skin Diseases due to Activated Neutrophils, Psoriasis, and Associated Arthropathy. Therapeutic Apheresis and Dialysis, 17: 477–483. doi: 10.1111/1744-9987.12113
- Issue published online: 7 OCT 2013
- Article first published online: 7 OCT 2013
- Manuscript Received: FEB 2013
- Granulocyte and monocyte adsorption apheresis;
- Multi-centered study;
- Neutrophilic dermatosis
Granulocyte and monocyte adsorption apheresis (GMA), an extracorporeal apheresis instrument whose column contains cellulose acetate (CA) beads, is designed to remove activated granulocytes and monocytes. We previously demonstrated that GMA was useful for treating neutrophilic dermatoses and associated arthropathy as it adsorbs Mac-1 (CD11b/CD18)-expressing neutrophils to the CA beads by the binding of complement component (iC3b) and CD11b expressed on activated neutrophils. The objective of this study is to further assess the clinical effectiveness of GMA in the treatment of neutrophilic dermatoses and associated arthropathy. The effect of GMA for skin lesions and joint lesions was assessed in 44 and 23 patients, respectively. Mac-1 expression on peripheral neutrophils was measured by flow cytometry. Skin lesions and arthropathy improved in 39 of 44 patients (88.6%) and 22 of 23 (95.6%), respectively. Mac-1 (CD11b/CD18) expression on the peripheral neutrophils, 27.1 ± 6.66 MFI (mean fluorescence intensity) before treatment, was reduced to 17.9 ± 3.02 MFI by GMA (P < 0.05). Clinical effectiveness of GMA for the treatment of intractable neutrophilic dermatoses and associated arthropathy was further confirmed.